← Human Trials & Peer-Reviewed Studies
Effect of endogenous cholecystokinin on postprandial gallbladder refilling. Ultrasonographic study in healthy subjects and in gallstone patients
Plain-language guide to PMID 7821124 (1995): double-blind randomized controlled trial study of Cholecystokinin (CCK) in 16 subjects, gallbladder and gallstones.
Key Facts
- PMID
- 7821124
- Journal
- Digestive diseases and sciences
- Year
- 1995
- Study type
- Randomized Controlled Trial
- Authors
- Cicala M et al. (5 authors)
- DOI
- 10.1007/BF02063946
What This Study Did, in Plain Language
What Was Tested
Researchers studied Cholecystokinin (CCK) in the context of gallbladder and gallstones in this randomized controlled trial publication.
To assess the role of CCK in GB refilling, a CCK-receptor antagonist, loxiglumide, or saline were infused intravenously in a random double-blind fashion after the ingestion of a liquid test meal in 16 healthy subjects.
Why It Was Studied
The postprandial release of cholecystokinin (CCK) regulates gallbladder (GB) contraction but little is known about the role, if any, of the still-elevated CCK blood levels on subsequent GB refilling.
Who Took Part
The abstract describes 16 subjects taking part.
By PubMed's age tags, the people studied were adults, both men and women.
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
Because people in this Cholecystokinin (CCK) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
As a double-blind Cholecystokinin (CCK) study, the assignments were hidden from both participants and investigators until the end.
The comparison arm used a placebo, so changes seen with Cholecystokinin (CCK) could be set against what happens without it.
What Was Measured
The postprandial release of cholecystokinin (CCK) regulates gallbladder (GB) contraction but little is known about the role, if any, of the still-elevated CCK blood levels on subsequent GB refilling.
Topics PubMed links to this paper include Cholecystokinin, Cholelithiasis, Eating, Gallbladder, Gallbladder Emptying, Proglumide and Ultrasonography.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Cholecystokinin (CCK) in 16 subjects in people with gallbladder and gallstones.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1995 (Digestive diseases and sciences), a journal based in United States.
More context: the Cholecystokinin (CCK) compound page, Gallbladder and gallstones research.
Our Notes on the Compound
Cholecystokinin (CCK): A gut and brain peptide hormone that stimulates gallbladder contraction and signals fullness.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.